David Hall

David brings a unique combination of clinical, scientific, and investment expertise to his role on the RoslinCT Board. With over six years of experience in clinical medicine across Australia and the United Kingdom—specialising in anaesthetics and trauma—David combines deep frontline healthcare insight with a strategic investment perspective shaped by his work in private equity.

Since joining GHO Capital in 2017, David has supported value creation across several portfolio companies, including Sterling Pharma Solutions. He currently works closely with the management teams at FairJourney Biologics and FotoFinder, where he serves on the board. His ability to navigate both scientific and commercial domains makes him a valuable partner to businesses driving innovation in the life sciences sector.

David holds an MBA with Distinction from London Business School, a Master of Public Health from the University of Newcastle (Australia), and a Bachelor of Medicine and Surgery with Honours from Monash University. Originally from Australia, he is a native English speaker and conversational in French, bringing an international perspective to his advisory work.